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Abstract
The CDC25A-CDK2 pathway has been proposed as critical for the oncogenic action of human epidermal growth
factor receptor 2 (HER2) in mammary epithelial cells. In particular, transgenic expression of CDC25A cooperates
with HER2 in promoting mammary tumors, whereas CDC25A hemizygous loss attenuates the HER2-induced
tumorigenesis penetrance. On the basis of this evidence of a synergism between HER2 and the cell cycle regulator
CDC25A in a mouse model of mammary tumorigenesis, we investigated the role of CDC25A in human HER2-positive
breast cancer and its possible implications in therapeutic response. HER2 status and CDC25A expression were
assessed in 313 breast cancer patients and we found statistically significant correlation between HER2 and CDC25A
(P = .007). Moreover, an HER2-positive breast cancer subgroup with high levels of CDC25A and very aggressive
phenotype was identified (P = .005). Importantly, our in vitro studies on breast cancer cell lines showed that the
HER2 inhibitor efficacy on cell growth and viability relied also on CDC25A expression and that such inhibition induces
CDC25A down-regulation through phosphatidylinositol 3-kinase/protein kinase B pathway and DNA damage response
activation. In line with this observation, we found a statistical significant association between CDC25A overexpression
and trastuzumab-combined therapy response rate in two different HER2-positive cohorts of trastuzumab-treated
patients in either metastatic or neoadjuvant setting (P = .018 for the metastatic cohort and P = .021 for the
neoadjuvant cohort). Our findings highlight a link between HER2 and CDC25A that positively modulates HER2-
targeted therapy response, suggesting that, in HER2-positive breast cancer patients, CDC25A overexpression affects
trastuzumab sensitivity.
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Introduction
Human epidermal growth factor receptor 2 (HER2) gene amplification
and/or protein overexpression characterize 15% to 25% of invasive
breast cancers and define a clinically important group of patients
[1,2]. The HER2-positive breast cancer group has traditionally been
associated with poor prognosis [1,3], but the advent of HER2-
targeted therapies has changed the natural course of the disease for
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a significant fraction of patients. Although HER2-positive breast
cancers display several genomic aberrations, they remain mainly depen-
dent on HER2 signaling for survival and growth and, consistent with
such dependency, are preferentially growth inhibited by HER2-specific
drugs [4]. In particular, the humanized monoclonal antibody trastuzu-
mab directed against the extracellular domain of HER2, when com-
bined with chemotherapy, has a significant impact on HER2-positive
breast cancer treatment, in both metastatic and adjuvant settings, de-
creasing the risk of relapse and prolonging patient survival [5–7].
Unfortunately, a relevant percentage of patients with HER2-positive
breast cancer exhibits an initial resistance to trastuzumab-based therapy
[8]. In the metastatic setting, primary resistance ranges from 44% to
64% for single-agent trastuzumab [9,10] and from 25% to 30% for
combination therapy [5,11,12].
Indeed, HER2-positive breast cancer is hardly a homogeneous dis-
ease and many other key pathways involving HER2 still need to be
unveiled. Moreover, the molecular mechanisms by which trastuzumab
inhibits tumor cancer growth and potentiates chemotherapy are still
not completely understood [13,14].
HER2 gene amplification/overexpression in breast cancer has been
associated with increased cell proliferation, cell motility, tumor inva-
siveness, and reduced apoptosis mainly through the RAS and phos-
phatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathways
[15]. Thus, the oncogenic effect of HER2 occurs through several
mechanisms, including cell cycle perturbation. Specifically, activation
of HER2 signal transduction promotes cell proliferation by shorten-
ing the G1 phase, and HER2 overexpression has been associated with
both up-regulation of cyclin D1 and down-regulation of the CDK
inhibitor p27 [16]. Accordingly, trastuzumab induces cell cycle G1
arrest through up-regulation of p27 [17] and decreased expression
of cyclin E [18].
Recently, it has been proposed that CDC25A-CDK2 pathway is
critical for the oncogenic action of HER2 in mammary epithelial cells
[19]. In particular, transgenic expression of CDC25A cooperates with
HER2 in promoting mammary tumors [20], whereas hemizygous
loss of CDC25A attenuated the penetrance of HER2-induced tumor-
igenesis [21].
CDC25A phosphatase is an essential component of the cell cycle
machinery and integrates the specific signals of checkpoint control in
response to DNA damage [22,23]. The activation of the DNA damage
response (DDR) causes cell cycle arrest and, depending on the extent
of the insult, mediates either DNA repair or premature senescence/
apoptosis of the damaged cell. Two fundamental component of the
DDR are the checkpoint kinases CHK1 and CHK2 that target
CDC25A to proteasome-dependent degradation, thus triggering cell
cycle arrest [23–26]. Therefore, CDC25Amisregulation can contribute
to genomic instability and several lines of evidence support a role for
CDC25A in cancer development [20,27]. Consistently, CDC25A is
aberrantly expressed and predicts poor patient prognosis in a significant
number of human cancers, including breast cancer [28,29]. Further-
more, we have previously shown that ectopic CDC25A overexpression
in primary human breast cells results in impaired DDR, enhancing
genomic instability at common fragile sites and consequently increasing
the chances of tumorigenic conversion [30].
On the basis of the evidence of a synergism between HER2 and
CDC25A in mouse model mammary tumorigenesis, we investigated
the relation between HER2 and CDC25A in human breast cancer to
understand whether CDC25A evaluation could contribute to a better
characterization of HER2-positive breast cancer patients.
We analyzed both HER2 status and CDC25A expression in dif-
ferent series of human breast cancers either treated or not with tras-
tuzumab. In particular, we found important clinical implications in
terms of response to trastuzumab treatment for the HER2-positive
tumors that overexpress CDC25A.
The effect of HER2 inhibition was also studied in HER2-positive
breast cancer cell line models showing differences in CDC25A expres-
sion levels. Our results highlighted a strong association among HER2,
CDC25A, and DDR induction, adding more evidence to the knowl-
edge of the HER2 overexpression effects on regulation of the cell cycle
checkpoints and cellular proliferation.
Materials and Methods
Patient Selections and Statistical Analysis
We analyzed both HER2 status and CDC25A expression in a
cohort of 313 patients, with breast carcinoma diagnosed between
1994 and 2000, at the San Raffaele Hospital (Milan, Italy) and
the Santa Chiara Hospital (Trento, Italy). Patients’ clinicopathologic
Table 1. Patient Characteristics (n = 313).
Age, median (range) 59 years (27–90)
Histology
Ductal 271 (86.58%)
Lobular 25 (7.99%)
Other 17 (5.43%)
pT
pT1 138 (44%)
pT2 135 (43.1%)
pT3 23 (7.3%)
pT4 17 (5.6%)
pN
pN0 140 (44.73%)
>pN0 173 (55.27%)
LVI
Yes 96 (30.67%)
No 217 (69.33%)
Grade
1 44 (14.06%)
2 163 (52.08%)
3 106 (33.86%)
Hormone receptor
ER (+) and/or PgR (+) 252 (80.5%)
ER (−) and PgR (−) 61 (19.5%)
HER2
Pos 74 (23.6%)
Neg 239 (76.4%)
Ki67
Pos 160 (51.1%)
Neg 153 (48.9%)
CDC25A
Median percentage of positive nuclei (range) 19 (0–84)
Pos 156 (49.8%)
Neg 157 (50.2%)
Chemotherapy
Yes 179 (57.19%)
No 97 (30.99%)
N/A 37 (11.82%)
Hormone therapy
Yes 225 (71.89%)
No 74 (23.64%)
N/A 14 (4.47%)
Follow up, median (range) 8 years (0–13)
LVI indicates lymphovascular invasion; ER, estrogen receptor; PgR, progesterone receptor; ER cutoff =
10; PgR cutoff = 10; Ki67 cutoff = 25.
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characteristics are summarized in Table 1. Representative tumor areas
were carefully selected by experienced pathologists from formalin-
fixed paraffin-embedded (FFPE) samples for tissue macroarrays. To
study the statistical association between HER2 status and CDC25A
expression, two-sided Pearson chi-squared test was used.
Kaplan-Meier method was used to evaluate statistical association
between HER2 status/CDC25A expression and both overall survival
(OS) and disease-free survival (DFS); OS was defined as the time
from date of surgery to death due to any cause. Patients were cen-
sored at the date of last follow-up. DFS was defined as the time from
surgery to recurrence or last follow-up (data available for 304 patients
of 313). Survival curves were plotted by using the Kaplan-Meier
method, and the significance of the associations was assessed using
the two-sided log-rank test.
To assess whether the association between CDC25A expression
and prognosis was independent of other variables, a multivariate re-
gression analysis was performed by the Cox proportional hazards
model. Age at diagnosis, histology, pT, pN, histologic grade, hormone
receptor status, lymphovascular invasion, chemotherapy, hormono-
therapy, and HER2 status were the variables used for the analysis.
The study of the correlation between CDC25A expression and trastu-
zumab therapy response was performed on two cohorts of patients: a
“metastatic cohort” of 16 patients with metastatic breast carcinoma
diagnosed between 1998 and 2007 and treated with trastuzumab as
first-line therapy at the Santa Chiara Hospital and a “neoadjuvant
cohort” of 13 patients with breast carcinoma diagnosed between
2008 and 2011 and treated with trastuzumab as neoadjuvant therapy
at the San Raffaele Hospital. For the metastatic cohort, response to tras-
tuzumab therapy was evaluated on the basis of clinical and radiologic
examination of the tumor before and after treatment using Response
Evaluation Criteria In Solid Tumors [31]. For the neoadjuvant cohort,
pathologic response at surgery was scored as follows: 1) complete, if no
invasive residual disease in breast and axilla was found, 2) partial, if the
residual tumor burden was inferior to the clinically estimated tumor
diameter, and 3) absent, if the residual tumor burden was identical
or higher than the clinically estimated tumor diameter (stable or pro-
gressive disease).
To study the statistical association between CDC25A expression
and trastuzumab therapy response, two-sided Pearson chi-squared
test was used.
SPSS version 17.0 was used for statistical analyses. P < .05 was
considered statistically significant.
This study has been approved by the ethical committee of both
the San Raffaele Hospital and the Santa Chiara Hospital.
HER2 Testing Methods
HER2 expression on both breast cancer cell lines and tissue macro-
arrays was detected by immunohistochemistry (IHC) using HercepTest
(Dako, Carpinteria, CA). Results were scored by intensity and percent-
age of staining on a scale from 0 to 3+ according to the American
Society of Clinical Oncology/College of American Pathologists guide-
lines [2]. Fluorescence in situ hybridization (FISH) testing for HER2
was performed on the same samples using the PathVysion HER2 DNA
Probe Kit (Abbott Molecular, Abbott Park, IL) according to the man-
ufacturer’s instructions. Slides were analyzed using Nikon 90i fluo-
rescence microscope (Nikon Instruments SpA, Florence, Italy) with
both a single-pass (green and orange) and a triple-pass filter band
[4′,6-diamidino-2-phenylindole (DAPI)/green/orange]; images were
captured by Genikon software (Nikon). A total of 100 neoplastic nuclei
were observed per each sample and FISH scoring ranges were based on
those determined for the US Food and Drug Administration–approved
test for HER2 gene alterations in breast cancer using a combined gene-
centromere probe [32,33].
Immunohistochemistry
All immunostains were performed after microwave oven heat-
based antigen retrieval, using citrate buffer at pH 6.0. The follow-
ing anti-CDC25A antibody clones were tested: 3H2016, 144, F-6,
N-15, M-191, 5H51 (Santa Cruz Biotechnology, Santa Cruz, CA),
Ab991, Ab989 (Abcam, Cambridge, MA), DCS-120 (Thermo
Scientific, Newington, NH), 3652 (Cell Signaling Technology,
Danvers, MA), C25600-01U (USBio, Swampscott, MA), and
PC733 (Merck Bio, Birmingham, United Kingdom). The best results
were achieved with the primary antibody anti-human CDC25A [rabbit
polyclonal (144), sc-97; Santa Cruz Biotechnology; 1:500 dilution].
The specificity of the immunostaining was also examined by a pre-
absorption test. The diluted primary antibody was mixed with a five-
fold (by weight) excess of the antigenic peptide (CDC25A 144 P sc-97P;
Santa Cruz Biotechnology) in a small volume (500 μl) of phosphate-
buffered saline and incubated for 2 hours at room temperature (RT)
before being used in the immunostaining. Microscopic observation
was performed using a Nikon Eclipse 80i and images were captured
and analyzed using Aperio ScanScope and Aperio ImageScope
Nuclear Algorithm (Nikon Instruments SpA). The median percent-
age of positive nuclei for CDC25A staining (19%) was considered
as cutoff.
Cell Lines
SKBR3, BT474, and MCF-7 breast cancer cell lines were obtained
from the American Type Culture Collection (ATCC, Manassas,
VA). SKBR3 were grown in McCoy’s 5a Medium (Invitrogen) sup-
plemented with 10% FBS (Invitrogen, Carlsbad, CA). BT474 and
MCF-7 were grown in Dulbecco’s modified Eagle’s medium/F12
medium (Invitrogen) supplemented with 10% FBS. All cell lines were
screened for mycoplasma using MycoAlert Mycoplasma Detection
Kit (Lonza, Basel, Switzerland) and grown in a humidified atmo-
sphere incubator with 5% CO2 at 37°C. SKBR3 and BT474 meta-
phase preparations were obtained by treating overnight with colcemid
(0.01 μg/ml); metaphase harvests were carried on by hypotonic treat-
ment with 0.075 M KCl/0.08% Na citrate (1:1) for 15 minutes and
fixation in methanol/acetic acid (3:1).
Transient Transfection
Transient transfections were performed using the pCMV6-AC–
CDC25A–GFP vector (OriGene, Rockville, MD) expressing the
full-coding sequence of human CDC25A (NM_001789.2) in fusion
with the C-terminal GFP tag. As a control, the pCMV6-AC–green
fluorescent protein (GFP) vector (OriGene) was used. MCF-7 cells
were seeded at 1 × 105 cells per well in six-well plate, 24 hours before
transfection. Cells were transfected inOpti-MEMmedium (Invitrogen)
with Lipofectamine 2000 reagent (Invitrogen), according to the manu-
facturer’s protocol. Six hours post-transfection, cells were switched into
antibiotic-free medium containing 10% FBS for further 24 hours.
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Immunofluorescence
Cells were fixed in 4% paraformaldehyde, permeabilized in 0.5%
Triton X-100 in phosphate-buffered saline, and immunostained
overnight with primary antibodies: anti-human CDC25A [rabbit
polyclonal (144), sc-97; Santa Cruz Biotechnology; 1:750 dilution],
anti-CK 8.18 [mouse; Novocastra (Newcastle, United Kingdom);
1:20 dilution], or anti-cERBB2 (rabbit; Dako; 1:1000 dilution).
The primary antibody was visualized using goat anti-rabbit IgG Alexa
Fluor 555 (Invitrogen; 1:750 dilution) or goat anti-mouse IgG Alexa
Fluor 488 (Invitrogen; 1:500 dilution). Samples were counterstained
with DAPI-Antifade (VECTASHIELD Mounting Medium; Vector
Laboratories, Burlingame, CA). Microscopic observation was per-
formed using a Nikon 90i and images were captured by Genikon
software (Nikon Instruments SpA).
Cell Line Treatments
Cell lines were grown to 70% to 80% confluence, then treated with
45 μM AG825 (Calbiochem, Darmstadt, Germany), a selective
adenosine triphosphate (ATP)-competitive inhibitor of the tyrosine
kinase activity of HER2, and incubated at 37°C for 16 hours. To
inhibit translation and determine the stability of CDC25A, SKBR3 cells
were incubated with 5 μg/ml cycloheximide (Sigma-Aldrich) at differ-
ent times (15, 30, 60, 240, and 360 minutes). To inhibit proteasome-
dependent degradation of proteins, SKBR3 cells were incubated with
50 μM proteasome inhibitor MG132 (Sigma-Aldrich) for 360 minutes.
SKBR3 and BT474 cells were treated with 3 μM CDC25A inhibitor
PM20 (Sigma-Aldrich), which competitively inhibits the activity of the
phosphatase by binding to its active site, and incubated at 37°C for
16 hours. Control samples were treated with vehicle alone (DMSO).
Western Blot Analysis
Immunoblot analysis was performed essentially as reported [29].
The following antibodies were used: anti-CDC25A (monoclonal,
F-6), anti-CHK1 (monoclonal, G4), anti-CHK2 (polyclonal), anti-
AKT1 (polyclonal; Santa Cruz Biotechnology), anti-pCDK1/2Y15
(polyclonal; Calbiochem), anti-pAKTS473 (monoclonal, D9E), anti-
pCHK1S345 (polyclonal), anti-pCHK2T68 (polyclonal), anti-pH2AX
(monoclonal, 20E3), anti-pHER2Y1248 (polyclonal; Cell Signaling
Technology), anti-CDK2 (monoclonal, 55; BD Transduction Labora-
tories, Franklin Lakes,NJ), anti–cERBB2 (polyclonal;DakoCytomation,
Carpinteria, CA), and anti-cleaved poly(ADP-ribose) polymerase
(PARP; monoclonal, E51; Epitomics, Burlingame, CA). β-Tubulin
antibody (monoclonal, DM1B; Neomarkers, Fremont, CA) was used
as a loading control.
Quantitative Reverse Transcription–Polymerase
Chain Reaction Analysis
Total RNAwas extracted from SKBR3 cells, either treated or not with
AG825, using the RNeasy Mini Kit (Qiagen, Hilden, Germany). For
reverse transcription–polymerase chain reaction, cDNA was synthesized
in a 20-μl reaction volume containing 5 μg of total RNA by the Super-
Script III First-Strand Synthesis System Kit (Invitrogen) according to
the manufacturer’s instructions. TaqMan analysis was performed in
triplicate using the Applied Biosystems predesigned assays for CDC25A
gene (Hs00947994_m1). Glyceraldehyde 3-phosphate dehydrogenase
(GAPDH ) (Hs99999905_m1) was used as reference gene.
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide Assay
SKBR3 and BT474 were plated into a 24-well plate at a density of
4 × 104 cells per well. The next day, the cell lines were treated either
with 45 μM AG825 or 3 μM PM20 for 96 hours. Each condition
was performed in six replicates and control samples were treated with
DMSO. Viability was determined by 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) assay [34], and 250 μl of
MTT (Sigma-Aldrich) solution (0.2 mg/ml in Opti-MEM; Invitrogen)
was added to each well and the plates were further incubated for
2 hours. The crystals were dissolved in 400 μl of DMSO for 10 min-
utes. The absorbance was measured at a wavelength of 570 nm. Results
were expressed as mean percentage of cell viability ± SE of six rep-
licates from a representative experiment that was repeated three
independent times.
Results
HER2 and CDC25A in Human Breast Cancer: Association
with Poor Prognosis
To investigate a possible link between HER2 and CDC25A in
human breast cancer, we analyzedHER2 status and CDC25A expres-
sion in 313 breast cancer patients for whom both clinical and patho-
logic data were available and none of them received trastuzumab
treatment (Table 1).
The identification of a CDC25A antibody suitable for IHC studies
on FFPE breast cancer tissues was a demanding task. After a careful
screen of the commercially available CDC25A antibodies, we found
that the CDC25A (144) rabbit polyclonal antibody sc-97, from Santa
Cruz Biotechnology, gave the best results in our assays. To validate
the specificity of this antibody, we transfected MCF-7 breast cancer
cells with either pCMV6-AC–GFP or pCMV6-AC–CDC25A–GFP
vector. Immunofluorescence analysis highlighted the specificity of
CDC25A antibody: The antibody detected a strong CDC25A expres-
sion, representing the GFP-CDC25A fusion protein, exclusively in
CDC25A–GFP–MCF-7–transfected cells and not in GFP–MCF-7–
transfected ones. Moreover, the immunofluorescence data underlined
the expected nuclear localization of CDC25A after DAPI counterstain-
ing (Figure 1A). CDC25A nuclear localization was observed also by
IHC on FFPE breast cancer tissue samples (Figure 1B). CDC25A
antibody preabsorption testing using the antigenic peptide (CDC25A
144 P sc-97P; Santa Cruz Biotechnology) completely abrogated
immunoreactivity (Figure 1B), validating the antibody specificity.
In 313 cases analyzed, nuclear CDC25A overexpression was detected
by IHC in 49.8% and HER2 was scored as positive by IHC and FISH
in 23.6% (Table 1 and Figure 2A). A statistically significant correlation
between CDC25A expression and HER2 gene status was found (P =
.007); in particular, 63.5% ofHER2-positive tumors showed CDC25A
overexpression (Figure 2B). No association was found between
CDC25A and Ki67 expression levels (P = .529), suggesting that the
correlation between CDC25A and HER2 is independent of the pro-
liferative index.
Furthermore, Kaplan-Meier curves showed that overexpression of
CDC25A was associated with the decrease of both OS (P = .045)
and DFS (P = .032; Figure 2, C and D). Although in the multivariate
analysis of prognostic factors on survival CDC25A expression failed
to show an independent influence on cancer-specific death (P =
.127), a significant stratification of mortality risk was identified
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when HER2 status and CDC25A expression were evaluated in com-
bination for their relative effect on survival. The group with the
highest mortality was the one in which breast carcinomas showed
both HER2 positivity (overexpression/amplification) and CDC25A
overexpression in terms of either OS (P = .005) or DFS (P = .002;
Figure 2, E and F ).
HER2 Stabilizes CDC25A Protein Levels in Human Breast
Cancer Cell Line SKBR3
To evaluate whether HER2 signaling impinged on CDC25A, we
treated with the specific HER2 inhibitor AG825 two HER2-positive
human breast cancer cell lines that showed differences in CDC25A
expression levels: SKBR3, positive for both CDC25A overexpression
and HER2 amplification (HER2/CDC25A double-positive cells),
and BT474, displaying basal level of CDC25A and HER2 amplifica-
tion (Figure 3A).
AG825 treatment efficiently reduced HER2 phosphorylation in
HER2-positive SKBR3 and BT474 cell lines, as assessed by the de-
crease of HER2Y1248 phosphorylation without any significant effect
on total HER2 levels. In HER2/CDC25A double-positive SKBR3
cells, inhibition of HER2 by AG825 resulted in a significant
down-regulation of CDC25A at both protein level and functional
activity, as assessed by inhibitory phosphorylation of its CDK sub-
strates (pCDK1/2Y15). No such strong effects, but a slight induction
of CDK inhibitory phosphorylation, associated to a limited reduction
of CDC25A levels, was observed in BT474 after HER2 chemical inhi-
bition (Figure 3B).
Figure 1. (A) CDC25A (144) sc-97 antibody (Santa Cruz Biotechnology) validation on the breast cancer cell line MCF-7. Immunofluorescence
with CDC25A antibody in theMCF-7 breast cancer cell line transfected with either pCMV-AC–CDC25A–GFP or pCMV-AC–GFP: The antibody
detected a strong CDC25A expression in the CDC25A-GFP–transfected MCF-7 cells compared to the pCMV-AC–GFP–transfected MCF-7
cells. DAPI counterstaining underlined the nuclear localization of CDC25A (red signal, CDC25A; green signal, GFP; blue signal, DAPI; yellow
signal, merge). (B) CDC25A (144) sc-97 antibody IHC validation on FFPE breast cancer tissue samples. CDC25A nuclear localization was
detected by IHC on FFPE breast cancer tissue sample (left); CDC25A antibody preabsorption testing using the antigenic peptide (CDC25A
144 P sc-97P; Santa Cruz Biotechnology) showed a complete block in the immunoreactivity (right).
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We next investigated the mechanism by which CDC25A was
downregulated in response to HER2 inhibitor treatment. AG852
failed to significantly affect CDC25A mRNA level, as measured by
quantitative reverse transcription–polymerase chain reaction, in SKBR3
cells (data not shown), indicating a post-transcriptional inhibition.
Thus, to analyze the protein stability of CDC25A upon HER2 inhibi-
tion, we determined the CDC25A protein half-life by treating SKBR3
cells with the protein synthesis inhibitor cycloheximide at different
time points, in the presence or absence of AG825. We found that
AG825 treatment associated with a decrease in the half-life of
Figure 2. (A) HER2 status by FISH and CDC25A expression by IHC in human breast cancer. Representative example of HER2-amplified
tumor (FISH HER2 positive): ratio Spectrum Orange–HER2 signals and Spectrum Green–centromere 17 signals > 2; the same case is
an example of CDC25A-overexpressing tumor (IHC CDC25A positive): all infiltrating ductal carcinoma cells show strong staining with
CDC25A antibody. Representative example of HER2-nonamplified tumor (FISH HER2 negative): ratio Spectrum Orange–HER2 signals
and Spectrum Green–centromere 17 signals < 2; the same case is an example of CDC25A-nonexpressing tumor (IHC CDC25A negative):
no expression of CDC25A is seen in the infiltrating ductal carcinoma cells. (B) HER2 gene status and CDC25A expression histogram; 63.5%
of HER2-positive breast cancer patients showed CDC25A overexpression and 54.4% of patients with HER2-negative breast cancer were
negative for CDC25A overexpression. (C and D) CDC25A expression significantly correlates with prognosis. Kaplan-Meier curves showed
that overexpression of CDC25A was associated with the decrease of both OS (P = .045) and DFS (P = .032). (E and F) Significative
stratification of mortality risk by combinations of HER2 status and CDC25A expression. The group of patients with the highest mortality
was the one with HER2/CDC25A double-positive breast carcinomas in terms of either OS (P = .005) or DFS (P = .002; purple curves).
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Figure 3. (A) CDC25A expression and HER2 expression/gene amplification in breast cancer cell lines. Immunofluorescence with
CDC25A and cERBB2 (Dako) antibodies revealed CDC25A overexpression (nuclear red signal) and HER2 overexpression (cytoplasmic
red signal) in SKBR3 cells and basal levels of CDC25A and HER2 overexpression in BT474 cells. Green signal is the immunofluorescence
staining of cytokeratin pair 8 and 18 (CK8.18) highlighting the cell cytoplasm; blue signal is DAPI counterstaining for nuclei. FISH analysis
showed HER2 amplification (red signals) in SKBR3 and BT474 metaphase spreads. (B) HER2 inhibition induces CDC25A down-regulation
of both protein expression and functional activity. Cell lines were treated with AG825 (45 μM) for 24 hours. Control cells were treated with
DMSO. Immunoblot data showed a decrease in CDC25A protein levels in HER2/CDC25A double-positive SKBR3 cells treated with AG825.
SKBR3 cells showed also a decreased in CDC25A activity after HER2 abrogation as measured by the increase of the inhibitory phosphor-
ylation of its CDK substrates, pCDK1/2Y15. No such strong effect was seen in BT474. AG825 treatment could inhibit the kinase activity of
HER2 as assessed by a decrease in HER2Y1248 phosphorylation with no effect on total HER2 levels in the HER2-positive cell lines, SKBR3
and BT474. (C) HER2 inhibition affects CDC25A protein stability in SKBR3. SKBR3 cells were treated with the protein synthesis inhibitor
cycloheximide (5 μg/ml) at different time points (0, 15, 30, 60, 240, and 360 minutes) in the presence or absence of AG825: Immunoblot
data showed that AG825 decreased the half-life of CDC25A protein from 60 to less than 15 minutes. β-Tubulin was used as a load-
ing control. (D) Ubiquitin/proteasome pathway is involved in the increased turnover of CDC25A after SKBR3 AG825 treatment. To inhibit
proteasome-dependent degradation of proteins, SKBR3 cells, either treated or not with AG825, were incubated with 50 μM proteasome in-
hibitorMG132 for 6 hours. CDC25A immunoblot analysis showed that inhibition of the proteasomeby treatmentwithMG132 rescuedCDC25A
down-regulation. β-Tubulinwas used as a loading control. (E) HER2 inhibition leads to CDC25A down-regulation through the PI3K/AKT pathway
and DDR activation. Cell lines were treated with AG825 for 24 hours. Control cells were treated with DMSO. Immunoblot data showed,
in AG825-treated SKBR3 cells, a decrease in AKT activity, as measured by the decrease in its phosphorylation on serine 473 (pAKTS473)
and no reduction of total AKT observed; CHK1 and CHK2 activation, through phosphorylation of their key sites, serine 345 and threonine 68,
respectively (pCHK1S345, pCHK2T68), with no effect on total CHK1 and CHK2 levels; and histone H2AX gamma phosphorylation (γH2AX).
No differences were observed in BT474 cells either with or without AG825 treatment. β-Tubulin was used as a loading control.
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CDC25A protein from 60 to less than 15 minutes. These data sug-
gested that HER2 expression impinged on CDC25A protein stabil-
ity (Figure 3C ).
We then examined whether the ubiquitin/proteasome pathway was
involved in the increased turnover of CDC25A observed after AG825
treatment. Inhibition of the proteasome by treatment with MG132
rescued AG825-induced CDC25A down-regulation (Figure 3D), in-
dicating that the reduced expression of CDC25A observed in SKBR3
cells after HER2 inhibition is due to enhanced proteasome-mediated
degradation.
These data suggest that the HER2 signaling may affect the stabil-
ity of CDC25A in HER2-positive breast cancer cells.
HER2 Inhibition Associates with CDC25A Down-Regulation,
PI3K/AKT Pathway Inhibition, and DDR Activation
HER2 overexpression induces the activation of the PI3K/AKT
pathway [15]. Since activated AKT is a negative regulator of both
CHK1 and CHK2 [35,36], the PI3K/AKT pathway suppresses
DNA damage–induced checkpoint activation. On these grounds,
we determined whether inhibition of HER2 in SKBR3 cells triggered
degradation of CDC25A by relieving PI3K/AKT-mediated inhibition
of the DDR.
We observed that AG825-mediated inhibition of HER2 in SKBR3
cells resulted in a marked reduction of AKT activity, as measured by
the decrease in its phosphorylation at serine 473; no reduction of total
AKT was detected. Furthermore, we noticed that HER2 inhibition
activated the two fundamental players of DDR, CHK1 and CHK2
checkpoint kinases, through phosphorylation of their key sites, serine
345 and threonine 68, respectively. The total levels of both CHK1
and CHK2 remained unchanged. No differences were observed in
BT474 cells either with or without AG825 treatment (Figure 3E ).
This result promoted us to further investigate a possible induction
of a DDR response following HER2 inhibition. C-terminal phos-
phorylation of histone H2AX (Ser139) (γH2AX) is required for the
assembly of repair complexes and induction of DDR. Remarkably,
we found that histone H2AX underwent gamma phosphorylation
(γH2AX) after pharmacological inhibition of HER2 only in SKBR3
cells (Figure 3E).
Taken together, these results are consistent with the hypothesis
that HER2 inhibition mediates cell cycle checkpoint activation and
DDR induction and this associates with CDC25A degradation in the
HER2/CDC25A double-positive breast cancer cell line SKBR3.
HER2 Down-Regulation Results in a Lower Viability
and Increased Cell Death of the CDC25A-Overexpressing
Cell Line
We next investigated whether the ability of the HER2 inhibitor
AG825 to affect cell growth and viability of breast cancer cells was
influenced by the levels of CDC25A expression.
Figure 4. (A and B) HER2 down-regulation affects both viability and cell death in the CDC25A-overexpressing cell line. SKBR3 and BT474
cells were treated or not with AG825 (45 μM) for 96 hours. Cell viability changes were measured by MTT assay. Results were expressed
as mean percentage of cell viability ± SE of six replicates from a representative experiment that was repeated three independent
times. HER2 down-regulation resulted in a lower viability of the CDC25A-overexpressing cell line (SKBR3) compared to the CDC25A
basal expressing cells (BT474) (A). Cell death was evaluated by immunoblot for cleaved PARP: PARP cleavage was greater in SKBR3
compared to BT474. β-Tubulin was used as a loading control (B). (C and D) CDC25A inhibition by PM-20 induces breast cancer cell death.
SKBR3 and BT474 were treated or not with PM-20 (3 μM) for 96 hours. Cell viability changes were measured by MTT assay as performed
for HER2 inhibition studies: A marked reduction in SKBR3 viability was observed (C); PM-20 significantly inhibited CDC25A phosphatase
activity, as evinced by increased pCDK1/2Y15 levels, and associated to increased apoptotic response, as deduced by increased PARP
cleavage. β-Tubulin was used as a loading control (D).
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To this end, we assessed the effect of HER2 inhibition on the cell
viability of the HER2-positive breast cancer cell models. We observed
that AG825 efficacy in reducing cell viability was much more marked
in HER2/CDC25A double-positive SKBR3 cells compared to the
BT474 cells that, although HER2 positive, express basal levels of
CDC25A. In particular, as determined by MTT assay, we found that
after AG825 treatment the SKBR3 viable cells were 18% compared to
69% of BT474 (Figure 4A).
To examine whether the marked reduction in cell viability of SKBR3
cells treated with the HER2 inhibitor was related to apoptosis, we
used PARP cleavage (cleaved PARP) as a surrogate marker for apoptosis
[37]. After pharmacological HER2 inhibition, the extent of PARP
Figure 5. Statistically significant correlation between CDC25A overexpression and trastuzumab response. (A) Metastatic cohort of
patients. (B) Neoadjuvant cohort of patients. Chi-squared test showed a statistically significant correlation between CDC25A overexpres-
sion and trastuzumab response in the metastatic cohort (P = .018), where 90% of patients with CDC25A overexpression showed partial
or complete response to trastuzumab, while the 66.7% of CDC25A-negative patients had stable or progressive disease (C). Chi-squared
test showed a statistically significant correlation between CDC25A overexpression and trastuzumab response in the neoadjuvant cohort
(P = .021), where 100% of patients with CDC25A overexpression showed partial or complete response to trastuzumab (D).
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cleavage was greater in SKBR3 compared to BT474 (Figure 4B), sup-
porting the notion that decreased viability of SKBR3 cells treated with
the HER2 inhibitor was due to increased apoptosis.
Similarly, chemical inhibition of CDC25A activity by PM-20 re-
sulted in increased pCDK1/2Y15 levels and associated with enhanced
apoptosis (Figure 4, C and D).
CDC25A Is a Potential Predictor of Response to
Trastuzumab Treatment
The data collected so far suggested that the concurrence of HER2
and CDC25A positivity hypersensitizes breast cancer cells to the
pharmacological inhibition of HER2.
On these grounds, we assessed the potential clinical relevance of
our findings and investigated whether CDC25A overexpression was
associated to trastuzumab therapy response rate.
To this end, we analyzed CDC25A expression by IHC in two
cohorts of HER2-positive patients that received trastuzumab either
for the treatment of metastatic disease (metastatic cohort, n = 16;
Figure 5A) or for neoadjuvant therapy of early-stage breast cancer
(neoadjuvant cohort, n = 13; Figure 5B). In both metastatic and
neoadjuvant cohorts of patients, CDC25A expression was evaluated
before trastuzumab treatment: In particular, we analyzed the primary
tumor sample for the metastatic cohort and the primary tumor biopsy
for the neoadjuvant cohort.
In agreement with the CDC25A overexpression data obtained in
the previously analyzed cohort of 313 breast cancer patients (63.5%
of HER2/CDC25A double-positive tumors), we observed CDC25A
overexpression in 62.5% of the metastatic cohort cases and in 69.2%
of the neoadjuvant ones.
After trastuzumab treatment, HER2 and CDC25A were analyzed
in the neoadjuvant cohort patients with either no response (2) or par-
tial response (5), for whom tumor samples were available: Interest-
ingly, these data completely overlapped with the ones obtained from
the primary tumor biopsy before therapy.
Most importantly, in the two studied sets of patients, we found
a statistically significant correlation between CDC25A overexpres-
sion and response to trastuzumab-combined therapy (P = .018 for
the metastatic cohort and P = .021 for the neoadjuvant cohort). In
Figure 6. HER2 inhibition in a CDC25A overexpression context restores the DDR through a PI3K/AKT-dependent mechanism. In
CDC25A-positive breast cancer cells, high levels of CDC25A, pushing the cell throughout the cell cycle transition, may induce an
impaired DDR machinery, bypassing the DNA damage–induced cell cycle arrest. In HER2/CDC25A double-positive breast cancer cells,
such DDR evasion could be enhanced by HER2 through CDC25A stabilization (A). In this context, HER2 down-regulation leads to AKT
inhibition that stops its inhibitory action on CHK1/CHK2; the activation of the checkpoint kinases promotes CDC25A degradation and
restores the DDR in checkpoint-proficient cells (B).
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particular, when patients were stratified according to CDC25A
status, we observed that among the cases overexpressing CDC25A
the fraction of partial/complete response was 90% in the metastatic
series and 100% in the neoadjuvant series. In the same series, the
response rate for CDC25A-negative cases was 33% and 50%, respec-
tively (Figure 5, C and D).
Together, the above data, although related to a limited number of
patients, support the notion of a relationship between CDC25A over-
expression and trastuzumab efficacy, indicating a CDC25A prog-
nostic relevance in the HER2-positive group of patients treated with
trastuzumab-combined therapy.
Discussion
HER2 overexpression confers a more aggressive phenotype to human
breast cancer and associates with poor prognosis. Two approved
therapies targeting HER2, the monoclonal antibody trastuzumab
and the tyrosine kinase inhibitor lapatinib, are clinically active against
HER2-positive breast cancer and these anti-HER2 drugs have changed
the natural history of the disease. However, therapeutic resistance to
trastuzumab or lapatinib, as either single agents or in combination with
chemotherapy in the metastatic setting, often occurs in a significant
proportion of these patients with HER2-overexpressing tumors [38].
This suggests that some tumors either inherently possess or acquire
mechanisms of resistance that allow escaping from HER2 inhibition,
thus hampering the efficacy of targeted therapies.
To fulfill the promise of personalized care, it is dramatically impor-
tant to improve both the understanding of the biologic features and
the knowledge of the clinical behavior for each individual HER2-
positive tumor. HER2 relationship with other signaling pathways
has not yet been totally clarified and unveiling previously unrecognized
HER2 interactions could allow a better outlining of human HER2-
positive breast cancer subgroups.
This study provides the first evidence of a link between CDC25A
and HER2 in breast cancer and demonstrates that the expression of
CDC25A affects the response to trastuzumab ofHER2-positive tumors.
In a series of 313 breast cancers, a statistically significant correla-
tion between CDC25A expression and HER2 gene status (P = .007)
was found, with 63.5% of HER2-positive tumors showing CDC25A
overexpression. In addition, such evaluation highlighted a group of
HER2-positive breast cancer patients characterized by CDC25A
overexpression that showed the highest mortality rate and therefore
a particularly aggressive phenotype (P = .005).
To better characterize this tumor subtype and the possible inter-
action between CDC25A and HER2, the HER2/CDC25A double-
positive human breast cancer cell line SKBR3 was chosen as an
in vitro model sharing a similar portrait. In these cells, HER2 inhibi-
tion was associated with proteasome-mediated degradation of
CDC25A, indicating that HER2 pathway may impinge on CDC25A
protein expression. Furthermore, in SKBR3 cells, CDC25A degrada-
tion triggered by HER2 inhibition was mediated by cell cycle check-
point activation and DDR induction. This observation is in line with
a previous study on a tumor-prone transgenic mouse model, showing
that HER2 signaling contributes to skin tumorigenesis by activating
the PI3K/AKT pathway, which in turn suppresses DNA damage–
induced checkpoint activation and prevents CDC25A from degradation
[39]. In fact, HER2 down-regulation in SKBR3 resulted in inhibition of
the PI3K/AKT pathway and was associated with degradation of
CDC25A: Treatment of SKBR3 with an HER2 chemical inhibitor
resulted in a marked reduction of AKT activity and in the activation
of the CHK1 and CHK2 checkpoint kinases. γH2AX was clearly
detected only in SKBR3-treated cells, providing additional evidences
that HER2 inhibition induced DDR in HER2/CDC25A double-
positive cells.
We previously showed that constitutive overexpression of CDC25A
in primary human mammary epithelial cells leads to DNA replication
stress and consequent checkpoint activation. Then, the prolonged
exposure to high levels of CDC25A, pushing the cell throughout the
cell cycle transition, may induce an impaired DDR machinery, bypass-
ing the DNA damage cell cycle arrest [30]. The present data suggest a
scenario where such DDR evasion in HER2/CDC25A double-positive
breast cancer cells could be enhanced by HER2 through CDC25A
stabilization. In this condition, HER2 down-regulation would lead to
AKT inhibition, consequently reliving its inhibitory action on CHK1/
CHK2. The activation of the checkpoint kinases would promote the
degradation of CDC25A and the DDR restoration in checkpoint-
proficient cells (see Figure 6).
Consistent with such a model, HER2 chemical inhibition resulted
in a much more dramatic induction of apoptosis in the CDC25A-
overexpressing cell line (SKBR3) compared to the CDC25A basal
expressing cells (BT474). This observation is in accord with a pre-
vious study that reported a particular sensitivity to trastuzumab-
induced apoptosis by SKBR3 compared to BT474 cells [40].
The data presented here indicate that the efficacy of the pharmaco-
logical inhibition of HER2 signaling, which affects cell growth and via-
bility of breast cancer cells, relies at least in part on CDC25A expression
and the concurrence of HER2 and CDC25A positivity in breast cancer
cells could hypersensitize breast tumor cells to HER2 inhibition.
Indeed, there was an association between CDC25A and trastuzumab-
combined therapy response: The CDC25A expression analysis in two
cohorts of HER2-positive patients that received trastuzumab either for
the treatment of metastatic disease or for neoadjuvant therapy of early-
stage breast cancer showed a statistically significant correlation between
CDC25A overexpression and response rate to trastuzumab-based therapy
(P = .018 for the metastatic cohort and P = .021 for neoadjuvant cohort).
It was recently reported that the pretreatment of a subset of triple-
negative breast cancer cells with epidermal growth factor receptor inhibi-
tors can markedly sensitize their apoptotic response to DNA-damaging
chemotherapy through the reactivationofDNAdamage signaling pathways
[41]. Thus, the higher response to trastuzumab-combined therapy of the
CDC25A-positive patients could be due to the inhibition of CDC25A
that makes these tumors more susceptible to DNA damage chemotherapy.
Taken together, the presented findings identify a subtype of
HER2-overexpressing breast cancer with high levels of CDC25A
and a very aggressive phenotype. In particular, the HER2/CDC25A
double-positive tumors may respond to HER2-targeted therapy be-
cause HER2 down-regulation results in decreased CDC25A-associated
kinase activity, DDR induction, and increased apoptosis, shedding light
into the mechanisms of HER2/CDC25A crosstalk.
Moreover, this study demonstrates that the interaction between
CDC25A and HER2 positively modulates the response to HER2
inhibitors: CDC25A expression analysis in a larger series of HER2-
positive breast tumors may validate its clinical use in identifying patients
with a better response to trastuzumab-combined therapy.
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